Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells

Figure 3

The combination strategy with HM1.24-targeted therapies and the current therapeutic regimen in MM. Induction therapy containing proteasome inhibitors and/or IMiDs and consolidation therapy with high-dose chemotherapy followed by autologous PBSCT induce favorable therapeutic effects; however, the existence of minimal residual disease or MM CSCs is related to relapse and refractoriness. To overcome the drug resistance of MM cells, active immunotherapy with HM1.24-derived peptides and dendritic cells from autologous PBSC harvests and passive immunotherapy with defucosylated AHM might be effective approaches along with lenalidomide in the treatment of MM.